Makary suggests lower PDUFA fees as reauthorization process begins
Regulatory NewsJoanne S. Eglovitch
Biologics License Application (BLA)Biologics/ biosimilars/ vaccinesBiotechnologyHealth Authority meeting and communication strategyLeadershipPDUFAPharmaceuticalsProduct developmentUnited StatesUS Food and Drug Administration (FDA)